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Abstract
Aims To test the hypothesis that delivery of integrated care augmented by a web-based disease management
programme and nurse coordinator would improve treatment target attainment and health-related behaviour.
Methods The web-based Joint Asia Diabetes Evaluation (JADE) and Diabetes Monitoring Database (DIAMOND)
portals contain identical built-in protocols to integrate structured assessment, risk stratification, personalized reporting
and decision support. The JADE portal contains an additional module to facilitate structured follow-up visits. Between
January 2009 and September 2010, 3586 Chinese patients with Type 2 diabetes from six sites in China were randomized
to DIAMOND (n = 1728) or JADE, plus nurse-coordinated follow-up visits (n = 1858) with comprehensive assessments
at baseline and 12 months. The primary outcome was proportion of patients achieving ≥ 2 treatment targets (HbA1c
< 53 mmol/mol (7%), blood pressure < 130/80 mmHg and LDL cholesterol < 2.6 mmol/l).
Results Of 3586 participants enrolled (mean age 57 years, 54% men, median disease duration 5 years), 2559 returned
for repeat assessment after a median (interquartile range) follow-up of 12.5 (4.6) months. The proportion of participants
attaining ≥ 2 treatment targets increased in both groups (JADE 40.6 to 50.0%; DIAMOND 38.2 to 50.8%) and there
were similar absolute reductions in HbA1c [DIAMOND 8 mmol/mol vs JADE 7 mmol/mol (0.69 vs 0.62%)] and
LDL cholesterol (DIAMOND 0.32 mmol/l vs JADE 0.28 mmol/l), with no between-group difference. The JADE
group was more likely to self-monitor blood glucose (50.5 vs 44.2%; P = 0.005) and had fewer defaulters (25.6 vs
32.0%; P < 0.001).
Conclusions Integrated care augmented by information technology improved cardiometabolic control, with additional
nurse contacts reducing the default rate and enhancing self-care. (Clinical trials registry no.: NCT01274364)
Diabet. Med. 00, 000–000 (2016)
Introduction
Achieving and maintaining recommended treatment targets
decreases the risk of diabetes-related vascular complications,
mortality and associated healthcare costs [1–4]. In the UK
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Prospective Diabetes Study, an 11-mmol/mol (1%) reduction
in mean HbA1c led to 21% fewer deaths, 14% fewer
myocardial infarctions and a 37% decrease in microvascular
complications [5]. Despite collective accord, there are major
treatment gaps attributable to suboptimum self-care, poor
adherence to treatment and clinical inertia, resulting in low
rates of treatment target attainment in both developed and
developing regions [6,7].
These barriers are amplified by systemic factors, especially
in developing countries. In China, for example, the majority
of chronic care occurs in an in-patient setting with most
clinical assessments and treatment covered or reimbursed;
however, in a primary or ambulatory care setting, many
laboratory tests and chronic medications require co-pay-
ments or are not reimbursed. Electronic medical systems
exist but are largely fragmented, resulting in duplication or
overlapping of consultations, investigations and medications.
Despite an initiative to promote primary care by establishing
community-based clinics, many patients prefer going to
hospitals for specialist care, with long waiting times and
short contact intervals. Patients typically return every 1–
2 months, mainly to collect medications, often without pre-
booking, assessment or education, and with high default
rates [8,9].
One area of focus is the lack of structure for documenting
risk factors and complications, as well as the arbitrary nature
of risk stratification and patient follow-up. In the USA, the
Institute of Medicine recommended the following strategies
to improve chronic care: redesign care processes based on
best practices, use information technology to manage clinical
data with decision support, transfer knowledge and skills to
team members to coordinate care and use performance and
outcome measures for quality control [10]. In a meta-analysis
of strategies for quality improvement, promotion of self-care
and team change were associated with a 4-mmol/mol
(0.37%) mean reduction in HbA1c, along with improvements
in LDL cholesterol and blood pressure (BP) [11].
Since 1995, the Chinese University of Hong Kong (CUHK)
Diabetes Care and Research Team has re-designed work-
flows and trained nurses to assess patients and deliver
protocol-based care. By changing workflows and through
task delegation, we were able to improve medication
adherence, with attainment of multiple targets and reduced
risks of cardiovascular-renal complications [12,13]. Based on
these prototypes, we designed the web-based Joint Asia
Diabetes Evaluation (JADE) portal, consisting of two mod-
ules. The comprehensive assessment (CA) module comprises
templates for periodic assessment, risk stratification, person-
alized reporting and automated decision support. The
follow-up module includes templates for documentation of
modifiable risk factors, hypoglycaemia and key events to
track clinical progress and reinforce adherence [14]. A
separate portal with a CA module identical to that of JADE,
was also created to help doctors establish a diabetes
monitoring database (DIAMOND) as a first step towards a
comprehensive quality improvement programme. In this
demonstration project, we examined the effectiveness of
delivering integrated care in China with or without nurse-
coordinated follow-up visits using the JADE and DIAMOND
portals, respectively, on cardiometabolic control and health
behaviours, including default rates.
Patients and methods
The study assessed a 1-year multicentre randomized non-
blinded quality improvement programme. Between January
2009 and September 2010, patients with Type 2 diabetes
aged ≥ 18 years were recruited from six tertiary hospitals in
China. Exclusion criteria included Type 1 diabetes, life-
threatening conditions, reduced life expectancy or inability
to understand the scope of the study. The study was
approved by the New Territories East Cluster Clinical
Research Ethics Committee and local institutional ethics
boards at each participating site. All participants provided
written informed consent.
A total of 3586 eligible patients were randomized in a 1:1
ratio to DIAMOND (CA only) or JADE (CA plus nurse-
coordinated structured follow-up). At each centre, random-
ization was performed using computer-generated codes kept
in sealed, opaque envelopes, numbered 1 to 600 prefixed by
the study site. Personnel at the site not participating in the
study opened the envelope and informed consenting partic-
ipants of their group assignment.
Each centre was given a grant to support an additional
CUHK project team-trained nurse to perform the CA, guided
by the JADE/DIAMOND portals and supervised by a
physician. Both doctors and nurses received training on the
use of the portals to perform a structured patient evaluation,
What’s new?
• The value of quality improvement programmes in the
management of chronic conditions has been established
in a number of prospective studies and meta-analyses.
• The effect of the Joint Asia Diabetes Evaluation (JADE)
programme, an information technology-augmented
integrated care model, on diabetes-related outcomes
has been demonstrated in several studies within devel-
oped healthcare systems.
• This study represents one of the few quality improve-
ment initiatives undertaken in a developing country and
is the first to answer the question of whether initiatives
such as JADE are effective in enhancing quality of care
in underfunded healthcare systems.
• Given the increasing demand for healthcare resources in
developing countries, quality improvement has the
potential to improve chronic care without substantial
additional costs.
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Table 1 Baseline characteristics of all randomized Chinese patients with type 2 diabetes
n DIAMOND JADE P
Number randomized 1728 1858
Demographics
Mean  SD age, years 1728 56.8  11.7 1858 56.1  11.6 0.096
Gender: men, n (%) 1728 941 (54.5) 1858 1011 (54.4) 0.98
Median (IQR) disease duration, years 1705 5.0 (1.0, 10.0) 1809 5.0 (1.0, 10.0) 0.725
Education, n (%) 1724 1849 0.001
< 6 years 168 (9.7) 132 (7.1)
6–11 years 415 (24.0) 424 (22.8)
> 11 years 1140 (66.0) 1291 (69.5)
Unemployed, n (%) 1724 1103 (64.0) 1850 1153 (62.3) 0.306
Tobacco use, n (%) 1712 1827 0.998
Never 1123 (65.6) 1202 (65.8)
Former 206 (12.0) 208 (11.4)
Current 383 (22.4) 417 (22.8)
Alcohol use, n (%) 1718 1830 0.773
Never 1187 (69.1) 1269 (69.3)
Physical activity ≥ 3 times/week, n (%) 1717 867 (50.5) 1849 991 (53.6) 0.064
SMBG ≥ weekly, n (%) 1576 677 (43.0) 1713 780 (45.5) 0.137
Adherence to balanced diet, n (%) 1719 1091 (63.5) 1852 1205 (65.1) 0.156
Median (IQR) follow-up, months 1728 12.5 (5.28) 1858 12.5 (3.98) 0.449
Complications and comorbidities, n (%)
Retinopathy 1681 228 (13.6) 1808 241 (13.3) 0.84
Sensory neuropathy 1722 143 (8.3) 1852 113 (6.1) 0.011
Chronic kidney disease, n (%) 1646 37 (2.2) 1789 37 (2.1) 0.717
All heart events including heart failure, n (%) 1726 164 (9.5) 1845 155 (8.4) 0.221
Stroke, n (%) 1720 54 (3.1) 1850 42 (2.3) 0.109
Peripheral vascular disease, n (%) 1556 164 (10.5) 1688 122 (7.3) 0.001
Risk categories, n (%) 0.483
Low: 1/2 1727 220 (12.7) 1855 251 (13.5)
High: 3/4 1727 1507 (87.3) 1855 1604 (86.5)
Treatments, n (%)
Lifestyle modification only 1728 385 (22.3) 1858 388 (20.9) 0.309
On oral antidiabetic drug 1728 1214 (70.3) 1858 1321 (71.1) 0.579
Insulin 1728 452 (26.2) 1858 512 (27.6) 0.345
Any BP drugs 1728 390 (22.6) 1858 420 (22.6) 0.98
Angiotensin-converting enzyme inhibitors 1728 33 (1.9) 1858 34 (1.8) 0.86
Angiotensin II receptor type 1 receptor blocker 1728 207 (12.0) 1858 220 (11.8) 0.898
Statins 1728 544 (31.5) 1858 597 (32.1) 0.676
Risk factor control
Mean  SD body weight, kg 1715 69.52  12.67 1845 69.57  12.62 0.911
Mean  SD waist circumference, cm
Women 682 87.15  9.97 713 85.96  10.19 0.028
Men 800 91.46  9.68 815 91.81  9.48 0.47
Mean  SD BMI (kg/m2) 1715 25.32  3.62 1845 25.18  3.58 0.246
Mean  SD diastolic BP (mmHg) 1694 78.4  10.4 1824 78.8  11.0 0.243
Mean  SD systolic BP (mmHg) 1694 125.8  15.8 1824 125.0  15.7 0.131
Mean  SD total cholesterol, mmol/l 1653 4.95  1.31 1785 4.91  1.16 0.47
Mean  SD HDL cholesterol, mmol/l
Women 751 1.26  0.31 799 1.29  0.34 0.06
Men 891 1.1  0.28 960 1.12  0.27 0.108
Mean  SD LDL cholesterol, mmol/l 1644 2.94  0.89 1768 2.92  0.88 0.446
Mean  SD haemoglobin, g/dl 1446 14.49  7.44 2545 14.31  5.77 0.443
Mean  SD HbA1c, % (mmol/mol) 1648 7.91 (53)  2.08 (15) 1788 7.78 (59)  1.95 (15) 0.057
Median (IQR) triglyceride, mmol/l 1654 1.54 (1.14) 1788 1.48 (1.22) 0.005
Median (IQR) urine albumin to creatinine
ratio, mg/mmol
1506 1.20 (2.75) 1606 1.25 (2.85) 0.059
Mean  SD estimated GFR, ml/min/1.73 m2 1646 122.2  38.74 1789 122.63  41.88 0.754
Obesity, n (%) 1539 1081 (70.2) 1607 1114 (69.3) 0.575
Dyslipidaemia, n (%) 1669 1551 (92.9) 1810 1668 (92.2) 0.385
Hypertension, n (%) 1707 1275 (74.7) 1835 1392 (75.9) 0.421
Macroalbuminuria, n (%) 1506 75 (5.0) 1606 89 (5.5) 0.64
Microalbuminuria, n (%) 1506 330 (21.9) 1606 385 (24.0) 0.322
Frequency of hypoglycaemic
episodes ≥ once/month, n (%)
1713 178 (10.4) 1847 185 (10.0) 0.712
Attainment of treatment targets, n (%)
HbA1c < 7.0% (53 mmol/mol) 1648 692 (42.0) 1788 811 (45.4) 0.047
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document care processes and communicate results of clinical
and laboratory assessments to participants. For participants
randomized to JADE, the additional nurse was trained to use
the follow-up module to manage follow-up appointments
and facilitate ongoing patient support between clinic visits,
while the DIAMOND group received usual care. Details of
the JADE programme have been published and are included
in Appendix S1 [15]. The CA report consists of 5-year
probabilities for coronary heart disease, heart failure, stroke
and end-stage renal disease, estimated using validated risk
equations [16–19]. Patients were classified into one of four
risk categories based on risk scores derived from risk
equations, presence or absence of cardiovascular-renal
disease, and an ensemble of metabolic risk factors. Each
risk category corresponded to a recommended care level that
determined frequency of structured follow-up visits and
intensity of care [14].
Automated reports provided to patients and physicians
contained trend lines of attained versus recommended
metabolic targets, 5-year probabilities of major events, and
risk categories. The physician report included triggered
reminders on treatment intensification, while the patient
report included practice tips to promote lifestyle changes,
treatment adherence and self-monitoring, in the local lan-
guage. Both participants and referring doctors in the
DIAMOND group received their respective reports followed
Table 1 (Continued)
n DIAMOND JADE P
BP < 130/80 (mmHg) 1694 662 (39.1) 1824 710 (38.9) 0.926
LDL cholesterol < 2.6 (mmol/l) 1644 600 (36.5) 1768 644 (36.4) 0.966
At least one target 1595 1211 (75.9) 1716 1300 (75.8) 0.911
At least two targets 1595 555 (34.8) 1716 624 (36.4) 0.347
All three targets 1595 105 (6.6) 1716 136 (7.9) 0.137
Quality of life
Mean  SD EQ-VAS 1715 83.01  12.10 1830 82.83  12.35 0.721
Mean  SD EQ-5D index 1708 0.91  0.13 1817 0.91  0.14 0.995
BP, blood pressure; DIAMOND, DIAbetes MONitoring Database; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation; SMBG,
self-monitoring of blood glucose; VAS, visual analogue scale.
3586 patients were assessed for 
eligibility
3586 patients underwent 
randomization
1728 patients 
assigned to 
DIAMOND group
1858 patients 
assigned to      
JADE group
552 (31.9%) 
Patients did not 
return for CA2
475 (25.6%)
Patients did not 
return for CA2
1176 (68.0%)
Included in the per-
protocol analysis
1383 (74.4%) 
Included in the per-
protocol analysis
373/1728 (21.6%) 
contacted by phone
*Death (n = 6)
*New CVD (n = 9)
Totally lost to follow-up 
(n = 179/1728 = 10.4%)
263/1858 (14%)
contacted by phone
*Death (n = 6)
*New CVD (n = 15)
Totally lost to follow-up
(n = 212/1858) 11.4% 
All were 
eligible 
FIGURE 1 Randomization and disposition of patients included in the intend to treat and per protocol analyses.
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by usual care. Participants assigned to JADE were recom-
mended to receive 2–4 h of diabetes education and at least
two additional contacts by the nurse coordinator (telephone
or face-to-face visits). Facilitated by the follow-up module,
nurses were asked to reinforce treatment and lifestyle
adherence, encourage self-monitoring of blood glucose
(SMBG) and remind them about structured follow-up
appointments that included documentation of laboratory
measurements, body weight, blood pressure, hypoglycaemia,
self-care and other major events in the JADE portal. The
nurse coordinator issued a follow-up report, discussed
cardiometabolic control and clarified concerns regarding
therapy. Participants in the lower risk categories (l or 2, with
few risk factors/complications) were recommended to have
structured follow-up visits every 4–6 months and those in
higher risk categories (3 or 4, with multiple risk factors and/
or complications) every 2–3 months. At the end of
12 months, all participants underwent repeat CA, and non-
returnees were contacted by telephone to ascertain health
status.
The primary outcome was the proportion of participants
attaining ≥ 2 treatment targets (HbA1c < 53 mmol/mol
(7%), BP < 130/80 mmHg, LDL cholesterol < 2.6 mmol/l)
after 12 months. Other outcomes included default rates,
change in quality-of-life measures, frequency of hypogly-
caemia, adherence to lifestyle modification/self-care activi-
ties, and new onset of physician-documented diabetes-related
endpoints. Events were recorded using standard forms, with
predefined diagnosis accompanied by a narrative, albeit not
adjudicated. Power calculation and statistical analyses
applied are available in Appendix S2.
Results
Between January 2009 and September 2010, 3586 eligible
participants, representing ~65% of all subjects considered
[mean age 56.5  11.6 years, 54.4%men,median (interquar-
tile range) disease duration of 5 (1–10) years, mean HbA1c
62  22 mmol/mol (7.85  2.02%)] were recruited from
patients already receiving treatment at the clinics. The primary
reasons for declining were testing costs and recurring travel to
study site. A total of 1728 participants were assigned to
DIAMOND and 1858 to JADE, with both groups having
similar characteristics at baseline (Table 1).
Between March 2011 and December 2013, after a median
(interquartile range) follow-up of 12.5 (4.6) months, 2559
out of 3586 randomized participants (71.4%) returned for
the second CA (CA2), with documentation of clinical and
biochemical data and event rates. A total of 1027 partici-
pants (28.6%) did not return for CA2, but 636 of those were
contacted by telephone for ascertainment of health status,
while 371 (10.3%) were lost to follow-up with no vitality
ascertainment. In all, 24 participants had a cardiovascular
event and 12 died. A final total of 2559 participants were
included in the per-protocol analysis (Fig. 1).
In the JADE group, 191 participants were in risk category
1–2, with the remaining 1192 in risk category 3–4. The mean
frequencies of nurse-coordinated follow-up visits in risk
categories 1–4 were 1.2, 1.8, 1.9 and 2.4 times per year,
respectively. Follow-up frequency for patients in DIAMOND
was not captured because the DIAMOND portal was not
designed to capture follow-up frequency.
Compared with baseline, the proportion of participants
attaining ≥ 2 treatment targets (DIAMOND 38.2 to 50.8%,
P < 0.01; JADE 40.6 to 50.0%, P < 0.01);
HbA1c < 53 mmol/mol (7%) (DIAMOND 45.8 to 61.1%,
P < 0.01, JADE 49.0 to 58.5%, P < 0.01) and LDL choles-
terol < 2.6 mmol/l (DIAMOND 36.4 to 52.9%, P < 0.01;
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FIGURE 2 Proportions of patients in the Diabetes Monitoring
Database (DIAMOND) and Joint Asia Diabetes Evaluation (JADE)
groups attaining treatment targets at repeat assessment after 1 year of
follow-up. Between-group comparisons adjusted for trial centre, age,
gender, disease duration and baseline value. All P-values for within-
group comparison (CA2 vs baseline) were P < 0.01 except that of
JADE on blood pressure (BP) < 130/80 mmHg (P = 0.239). No
significant difference for changes in target achievement between
groups. Only patients with paired data for baseline and second
comprehensive assessment (CA2) are included in analysis. SMBG, self-
monitoring of blood glucose.
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JADE 39.5 to 53.4%, P < 0.01) increased similarly, with no
between-group difference (Fig. 2). The absolute change in
HbA1c [DIAMOND 8 mmol/mol, JADE 7 mmol/mol
(DIAMOND 0.69%, JADE 0.62%); P = 0.473] and LDL
cholesterol (DIAMOND 0.32 mmol/l, JADE 0.28 mmol/
l; P = 0.286) was similar in each group (Table 2). The
proportion of participants with BP < 130 mmHg fell in the
DIAMOND group but remained unchanged in the JADE
group (DIAMOND 40.6 to 34.6%, P < 0.01; JADE 39.2 to
37.4%, P = 0.239) with no between-group difference
(Fig. 2). More patients had a reduction in systolic BP of
≥ 10 mmHg (DIAMOND 18.4 vs JADE 22.2%; P = 0.052)
and in diastolic BP of ≥ 5 mmHg (DIAMOND: 26.6% vs
JADE: 33.5%, P = 0.018) in the JADE than the DIAMOND
group (Table 2).
Both groups reported improved adherence to self-care
behaviours (P < 0.01 compared with baseline) with more
patients in the JADE group performing SMBG at study end
(50.5 vs 44.2%, P = 0.005; Fig. 1). In the DIAMOND
group, 16 of 205 participants (7.8%) and 21 of 199 (10.6%)
in the JADE group stopped smoking, with no between-group
difference (Table 2).
At study end, more participants in the JADE group
initiated oral antidiabetic drug treatment (DIAMOND
19.1% vs JADE 25.1%; P = 0.041). New use of antihy-
pertensive/lipid-lowering drugs was significantly different
from baseline but similar in both groups. The proportion of
participants reporting hypoglycaemic episodes at least
monthly fell similarly in both groups (DIAMOND 11.9 to
6.7%, P < 0.001; JADE 10.8 to 7.3%, P = 0.002). Scores
on the EuroQol health status index, the EQ-5D (visual
analogue scale), tended to improve in the JADE group and
declined in the DIAMOND group, with no between-group
difference.
Table 2 Mean changes for HbA1c, blood pressure, lipids and quality of life measures as well as changes in medications and self-care behaviour in the
DIAMOND and JADE groups who underwent comprehensive assessments at baseline and after 12 months
Month 12: baseline visit
Valid
number DIAMOND (95% CI)
Valid
number JADE (95% CI) Crude P value
Adjusted
P value*
Metabolic control
Median (IQR)
HbA1c, mmol/mol
944 8 (9, 7) 1112 7 (8, 6) 0.372 0.473
Median (IQR)
HbA1c, %
944 0.69 (0.81, 0.57) 1112 0.62 (0.73, 0.50) 0.372 0.473
Median (IQR)
SBP, mmHg
1130 2.43 (1.49, 3.37) 1326 1.64 (0.77, 2.50) 0.221 0.091
Median (IQR)
DBP, mmHg
1130 0.25 (0.37, 0.86) 1326 1.03 (1.65, 0.41) 0.004 0.057
Median (IQR) LDL
cholesterol, mmol/l
924 0.32 (0.38, 0.27) 1023 0.28 (0.34, 0.23) 0.335 0.286
Median (IQR) body
weight, kg
1148 0.13 (0.48, 0.22) 1353 0.02 (0.29, 0.25) 0.612 0.482
HbA1c reduction
≥ 0.5%, n (%)
944 400 (42.4) 1112 420 (37.8) 0.034 0.223
Systolic BP reduction
≥ 10 mmHg, n (%)
1130 208 (18.4) 1326 294 (22.2) 0.021 0.052
Diastolic BP reduction
≥ 5 mmHg, n (%)
1130 301 (26.6) 1326 444 (33.5) < 0.001 0.018
LDL cholesterol
reduction ≥ 30%,
n (%)
924 193 (20.9) 1023 206 (20.1) 0.682 0.511
Body weight reduction
≥ 3%, n (%)
1148 232 (20.2) 1353 259 (19.1) 0.503 0.344
Smoking cessation,
n (%)
205 16 (7.8) 199 21 (10.6) 0.346 0.759
Add on medication†,
n (%)
Insulin 50/885 (5.6) 71/1027 (6.9) 0.295 0.175
Oral antidiabetic drug 67/350 (19.1) 96/383 (25.1) 0.199 0.041
BP-lowering drugs 63/894 (7.1) 55/1072 (5.1) 0.098 0.126
Lipid-regulating drugs 106/793 (13.4) 110/899 (12.2) 0.337 0.586
Quality of life
Median (IQR)
EQ-5D index
1039 0.028 (0.018, 0.038) 992 0.037 (0.027, 0.047) 0.192 0.146
Median (IQR) EQ-VAS 1001 0.80 (1.52, 0.086) 967 0.66 (0.12, 1.44) 0.005 0.478
BP, blood pressure; DIAMOND, DIAbetes MONitoring Database; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation.
*Adjusted for age, gender, disease duration, baseline value and trial centre.
†New users/non users at baseline.
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Amongst returnees for CA2, the rate of incident diabetes-
related complications including, chronic kidney disease,
sensory neuropathy, foot ulcer, loss of visual acuity or
advanced eye disease, were similar between groups (Table 3).
There were fewer defaulters in the JADE group than in the
DIAMOND group (25.6 vs 32.0%; P < 0.001). At baseline,
defaulters were younger (55.8 vs 56.7 years; P = 0.036),
were more likely to have a positive smoking history (35.2 vs
33.9%; P = 0.002), were less well educated (> 11 years’
education, 61.40 vs 70.70%; P = 0.017), and had worse
cardiometabolic risk profile and higher rates of chronic
kidney disease (3.20 vs 1.70%; P = 0.007) and macroalbu-
minuria (8.10 vs 4.20%; P < 0.001), despite similar disease
duration. Although defaulters were more likely to be treated
with insulin (30.70 vs 25.30%; P = 0.001) and lipid-
lowering drugs (38.20 vs 33.90%; P = 0.016), they were
less likely to adhere to regular physical exercise (46.10 vs
54.50%; P < 0.001) and achieve HbA1c target (37.20
vs 46.40%; P < 0.001) or ≥ 2 treatment targets (30.60 vs
37.40%; P < 0.001; Table 4).
Discussion
In this 12-month randomized quality improvement pro-
gramme in Chinese patients with Type 2 diabetes, we used a
multi-component web-based portal to integrate care delivery
focusing on workflow, task delegation and information
technology. Irrespective of nurse support, both groups had
improved cardiometabolic control, increased attainment of
multiple treatment targets, enhanced self-care and smoking
cessation. The additional contacts by nurses during the
follow-up period did not further improve cardiometabolic
control but reduced default rates and improved SMBG.
Given the multi-component nature of the JADE/DIA-
MOND programme, it was challenging to identify the
specific components that drove treatment effects, although
these elements are known to individually and collectively
improve diabetes care [11]. In a 7-year observational study
consisting of 172 patients with Type 2 diabetes without
history of cardiovascular-renal complications, structured
care provided by a diabetologist-nurse team reduced cardio-
vascular-renal disease and mortality by 50–70% compared
with those attended by generalists in the medical clinic within
the same institution [20]. In another study evaluating peer
empowerment in participants who also received structured
care through the JADE programme, HbA1c was reduced by
0.3% (3 mmol/mol), with improvement in multiple targets
attained and self-care [21].
The addition of nurse-coordinated follow-up visits in the
JADE group did not further enhance glycaemic control or
target attainment. That said, JADE participants were more
likely to have stable BP control and increased SMBG and were
less likely to default, suggesting that ongoing support can be
translated into beneficial actions. The nurse provided was
envisaged to take on a multifunctional role to promote
adherence to the care protocol and reinforce patient educa-
tion. Given the translational nature of this study that exam-
ined integrated care in real-world settings, we used data
documented in the follow-up module of the JADE portal to
assess protocol adherence. We did not rigorously enforce and
strictly record compliance to protocol-recommended practice;
thus, it was not possible to fully appraise intervention fidelity.
Table 3 New onset of diabetes-related endpoints in JADE and DIAMOND study groups
n
DIAMOND,
n (%) n
JADE,
n (%)
All patients with vitality status 1549 1646
Self-reported new cardiovascular event
(coronary heart disease or stroke)
30 (1.9) 42 (2.5)
Returnees 1176 21 (1.8) 1383 27 (2.0)
Non-returnees 373 9 (2.4) 263 15 (5.7)
Death 6 (0.3) 6 (0.18)
Returnees for repeat assessment 1176 1383
New chronic kidney disease: 50% loss of
estimated GFR
900 16 (1.8) 1026 12 (1.2)
New appearance of sensory neuropathy in
patients without sensory neuropathy at baseline
1072 49 (4.6) 1048 52 (5.0)
Remission of sensory neuropathy in patients with
sensory neuropathy at baseline
96 70 (72.9) 75 53 (70.7)
Worsening or new appearance of diabetic retinopathy 992 28 (2.8) 869 37 (4.3)
Improvement of diabetic retinopathy in patients
with diabetic retinopathy at baseline
59 59 (100) 45 41 (91.1)
Improved visual acuity in at least one eye 563 164 (29.1) 657 228 (34.7)
Deteriorated visual acuity in at least one eye 570 216 (37.9) 658 239 (36.3)
DIAMOND, DIAbetes MONitoring Database; JADE, Joint Asia Diabetes Evaluation.
Worsening /improvement of diabetic retinopathy is defined as advancement or stabilization in the grading by ophthalmologist (pre-
proliferative, proliferative, advanced).
n includes returnees and a subset of defaulters who could be reached for health status assessment at study end.
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Table 4 Population characteristics at baseline for returnees versus defaulters
Returnees Defaulters P
Total number of participants, n (%) 2559 (71.4) 1027 (28.6) –
Demographics
Mean  SD age, years 56.70  11.56 55.80  11.83 0.036
Women, % 54.4 54.5 0.942
Education, % < 0.001
< 6 years 6.7 12.7
6–11 years 11.6 11.8
> 11 years 70.7 61.4
Unemployed, % 64.2 60.5 0.041
Smoking, % 0.428
Never 66.1 64.8
Former 11.6 11.8
Current 22.3 23.4
Alcohol consumption, % 0.002
Never 67.8 72.8
Former 6.4 7.5
Occasional 16.9 11.7
Regular 8.9 8.0
Physical activity ≥ 3 times per week, % 54.5 46.1 < 0.001
SMBG ≥ weekly, % 45.1 42.4 0.163
Mean  SD disease duration, years 6.43  6.40 6.22  6.11 0.369
Complications and comorbidities, %
Chronic kidney disease 1.7 3.2 0.007
Coronary heart disease 9.0 8.4 0.548
Stroke 3.0 1.9 0.052
Peripheral vascular disease 9.5 7.3 0.052
Retinopathy 13.9 12.5 0.282
Sensory neuropathy 7.0 7.6 0.489
Risk categories 0.101
Low (1/2) 13.8 11.7
High (3/4) 86.2 88.3
Treatments, %
Lifestyle modification only 21.2 22.3 0.487
On oral antidiabetic drug 71.4 69.0 0.163
Insulin 25.3 30.7 0.001
On lipid drugs 33.9 38.2 0.016
Statins 30.7 34.7 0.021
On BP drugs 23.2 21.0 0.154
ACE inhibitors 2.0 1.6 0.386
AT1 receptor blockers 12.3 11.0 0.279
Risk factor control
Mean  SD body weight, kg 69. 68  12.34 69.19  13.36 0.308
Mean  SD BMI, kg/m2 25.68  3.58 25.16  3.64 0.361
Mean  SD waist circumference, cm
Women 86.50  10.11 86.68  9.90 0.769
Men 91.44  9.38 92.09  10.04 0.214
Mean  SD diastolic BP, mmHg 77.77  9.6 77.76  9.58 0.977
Mean  SD systolic BP, mmHg 126.03  15.07 126.72  15.48 0.225
Mean  SD total cholesterol, mmol/l 4.90  1.18 4.99  1.37 0.073
Mean  SD HDL cholesterol, mmol/l
Women 1.29  0.32 1.26  0.33 0.118
Men 1.12  0.28 1.08  0.27 0.001
Mean  SD LDL cholesterol, mmol/l 2.90  0.86 3.00  0.94 0.005
Mean  SD haemoglobin, g/dl 14.44  6.85 14.27  6.05 0.524
Mean  SD HbA1c, % (mmol/mol) 7.70 (61)  1.91 (14) 8.20 (66)  2.24 (17) < 0.001
Median (IQR) triglyceride, mmol/l 4.80 (4.15, 5.53) 4.88 (4.19, 5.58) 0.286
Median (IQR) urine albumin to creatinine ratio, mg/mol 1.19 (0.65, 3.25) 1.35 (0.62, 4.23) 0.059
Mean  SD estimated GFR, ml/min/1.73 m2 120.7  39.6 126.7  42.1 < 0.001
Obesity, % 69.3 70.7 0.447
Dyslipidaemia, % 92.4 92.7 0.755
Hypertension, % 75.6 74.6 0.542
Macroalbuminuria, % 4.2 8.1 < 0.001
Microalbuminuria, % 22.8 23.3 0.791
Attainment of treatment targets, %
HbA1c < 7.0% (53 mmol/mol) 46.4 37.2 < 0.001
BP < 130/80 mmHg 50.0 47.1 0.154
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In China, delivery of chronic care is fragmented and
infrastructure and capacity for team-based care are still
evolving. Nurses for instance, are often tasked with simple
procedures such as teaching insulin injection and SMBG or
performing blood glucose tests. Furthermore, patients are
less willing to engage nurses, preferring to consult directly
with doctors. As such, their abilities to educate and empower
patients may be less advanced compared with fully trained
diabetes nurses. This may partially explain the lack of
difference between the two groups. Also, the nurse coordi-
nators in the present study received basic training in diabetes
care, but, unlike case managers, were not empowered with
treatment authority. In a meta-analysis, quality improvement
initiatives that included case managers authorized to adjust
medications without awaiting physician approval substan-
tially improved patient care [22].
Because cultural factors are an important component in
education, we examined this result in light of education
programmes implemented in Chinese populations. In a 1-year
prospective study in Hong Kong, a structured nurse educa-
tion programme centred on cardiovascular disease risk every
3 months (mean total time 2.5 h) improved HbA1c, LDL
cholesterol and BP (diastolic) compared with a control group
[23]. In Taiwan, the introduction of multidisciplinary care,
combined with 2 h of diabetes education every 3 months for
1 year resulted in a 2-mmol/mol (0.22%) reduction in
HbA1c, with a nadir of 0.4% (4 mmol/mol) at 9 months,
without changes in oral antidiabetic medications [24]. In the
JADE group, we also recommended nurses to deliver at least
2 h of education after the CA, but in a single session rather
than multiple sittings. In a meta-analysis, the benefit of
patient self-care education on HbA1c was most pronounced
immediately after the intervention, with effects waning by 1–
3 months [25]. In the Taiwanese study, subjects received
initial diabetes education followed by repeated reinforcement
sessions every 3 months for 1 year. The reduction in HbA1c
was evident at 3, 6 and 9 months but lost significance by
1 year, suggesting that physician or patient fatigue and loss
of adherence may need to be addressed [24].
The fact that all participants benefitted from risk stratifi-
cation with written feedback during the initial consultation
might have contributed partially to a lack of separation and
improvement in both groups. The proportion of participants
with ≥ 2 treatment targets increased from 38.2 to 50.8% in
the DIAMOND group and from 40.6 to 50.0% in the JADE
group. Another reason for the lack of between-group
difference was patient-structured follow-up frequency in
JADE. In the low-risk category (care levels 1 and 2), the
portal recommended 1–2 structured follow-up visits per year
and 4–5 visits for the high-risk group (care levels 3 and 4).
However, in the JADE group, the documented number of
visits in the portal was 1.7 in participants at low risk and 2.0
in participants at high risk, the latter accounting for 86% of
the JADE group. Given the fragmented nature of follow-up
medical visits in China, we anticipated the additional nurse-
coordinated visits to improve follow-up frequency. The low
number of these structured visits might have nullified the
expected benefits, which highlights the challenges of imple-
menting integrated care models in countries with traditional
healthcare and financing systems. Moreover, patients’ per-
spectives need to be considered, as additional visits for a
silent disease like diabetes may not be welcomed because of
the extra time, tests and costs involved. By study design,
there was no documentation of interval measurements
between baseline and repeat CA2 in the DIAMOND group.
Thus, although a variance might have existed between the
two groups, the failure to fully comply a structured follow-
up and education programme in the JADE group might have
attenuated these differences by study end. Similar observa-
tions have been reported previously [24–26].
Despite the lack of between-group differences in car-
diometabolic control, the default rate, defined a priori, was
lower in the JADE than in the DIAMOND group. The
defaulters had higher HbA1c and LDL cholesterol, while
concurrently were more likely to be prescribed insulin and
lipid-loweringdrugs.Defaulterswere younger,more likely tobe
in paid employment and were less likely to exhibit good self-
care behaviours. Patients less willing to participate in self-care
behaviours become increasingly dependent on polytherapy and
with chronicity, drug regimens might become more complex,
which could further exacerbate non-adherence behaviours [27].
The present study has several limitations. Firstly, this was a
real-world application of integrated care augmented by
information technology in China, where healthcare resources
are limited. All six participating sites are leading centres,
although many of the recommended tests in the CA were not
Table 4 (Continued)
Returnees Defaulters P
LDL cholesterol < 2.6 mmol/l 37.1 34.8 0.206
At least one target 72.7 70.4 0.171
At least two targets 37.4 30.6 < 0.001
All three targets 7.9 5.3 0.006
Quality of life
Mean  SD EQ-VAS score 83.38  11.97 81.75  12.80 < 0.001
Mean  SD EQ-5D index score 0.91  0.14 0.92  0.14 0.156
BP, blood pressure; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation; SMBG, self-monitoring of blood glucose.
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reimbursed in an ambulatory setting. Unlike drug-based
clinical trials, none of the participants were compensated for
their participation or diagnostic/care-related expenditures.
This might have led to selection of a more affluent popula-
tion, although missing values for laboratory tests were found.
As participating sites were selected from cosmopolitan cities,
our findings cannot be extrapolated to rural populations.
Secondly, while this was a randomized quality improvement
programme, the treating doctors were not blinded to patient
assignment and contamination was possible with partici-
pants in both the DIAMOND and JADE groups managed by
the same physicians. Notwithstanding, the large sample size
involving multiple centres, as well as the documentation of
default rates/features known to be associated with higher
mortality and treatment costs [28–30] are major strengths.
In the present study, we did not observe enhanced
cardiometabolic control with the addition of a nurse coor-
dinator to the web-based CA module, although we did
observe a reduction in default rates and improved SMBG.
We also verified that incorporating a quality improvement
programme using an innovative care platform, such as the
JADE programme, is both feasible and effective in a low-
resource setting, albeit not without challenges. This proto-
type allowed the combining of logistics, task delegation and
information technology to increase the efficiency and effec-
tiveness of integrated care delivery with improvements in
cardiometabolic control and self-care, as well as reduced
clinical inertia.
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